Parallax Volatility Advisers
ITCI

Parallax Volatility Advisers’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Parallax Volatility Advisers’s Portfolio ITCI Stock Details ITCI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-8,900
Closed -$228K – 3241
2020
Q3 		$228K Buy
+8,900
New +$203K ﹤0.01% 2504
2017
Q4 		– Sell
-120,000
Closed -$1.89M – 5111
2017
Q3 		$1.89M Buy
+120,000
New +$1.76M ﹤0.01% 867
2015
Q4 		– Sell
-5,000
Closed -$200K – 4096
2015
Q3 		$200K Buy
+5,000
New +$163K ﹤0.01% 1813

Other funds holding ITCI

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
DKCM
Davidson Kempner Capital Management New York $7.33B AUM 56.47% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Parallax Volatility Advisers's ITCI Position: Q4 2020 in Review

Parallax Volatility Advisers sold out of Intra-Cellular Therapies Inc. (ITCI) in Q4 2020, closing a stake of 741 shares — an estimated $19K sold.

Parallax Volatility Advisers first reported a position in ITCI in Q3 2017 and held it in 5 quarters. The position peaked at $1.55M in Q3 2017. 178 funds tracked by Wall St. Rank hold ITCI as of Q4 2020.

  • Parallax Volatility Advisers reported no remaining Intra-Cellular Therapies Inc. position as of Q4 2020 after selling out during the quarter.
  • Parallax Volatility Advisers sold 741 Intra-Cellular Therapies Inc. shares in Q4 2020, an estimated $19K.
  • Parallax Volatility Advisers first reported a position in Intra-Cellular Therapies Inc. in Q3 2017 and held it in 5 quarters.
  • Parallax Volatility Advisers's Intra-Cellular Therapies Inc. position peaked at $1.55M in Q3 2017.
  • 178 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q4 2020.

Based on Parallax Volatility Advisers's 13F filing for Q4 2020, filed 16 Feb 2021.